Verastem, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

20 Mar 2025

VSTM

10-K: Verastem Oncology Reports Progress in LGSOC, Pancreatic Cancer, and NSCLC Programs; Announces 2024 Financial Results

Verastem Oncology highlights FDA priority review for avutometinib plus defactinib in KRAS mutant recurrent LGSOC and advancements in other pipeline programs alongside its 2024 financial results.

NASDAQ

14 Mar 2024

VSTM

Verastem, INC

10-K: Verastem Oncology Reports Promising Clinical Trial Progress and Financial Results for 2023

Verastem Oncology reports significant advancements in its clinical programs, including the initiation of a Phase 3 trial for its lead drug combination and positive data readouts, alongside its full year 2023 financial results.